Evaluating Efficacy of Pregabalin in Oncology Patients with Neuropathic Pain
2 Fatih Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, İstanbul, Türkiye
3 Kartal Eğitim ve Araştırma Hastanesi, Radyasyon Onkolojisi Kliniği, İstanbul, Türkiye
4 Gazi Üniversitesi Tıp Fakültesi, Algoloji Bilim Dalı, Ankara, Türkiye DOI : 10.5152/tftrd.2015.78889 Objectives: This study aims to evaluate the efficacy of pregabalin in oncology patients, which has been frequently used in recent years in the treatment of neuropathic pain.
Patients and methods: Between January 2014 and September 2014, 30 oncology patients (17 females, 13 males; mean age 39.9 years; range 28 to 52 years) who were diagnosed with neuropathic pain were included. Baseline visual analog scale (VAS) and the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scores were recorded. The VAS and LANSS scores were recorded at one and three months among patients receiving pregabalin therapy (300 mg/day).
Results: Visual analog scale and LANSS values before the treatment were found 76.83 and 16.70 respectively, 66.16 and 12.83 at the first month, 46.16 and 8.93 at the third month.
Conclusion: Our results show that, pregabalin that has been frequently used in recent years for neuropathic pain in the practice of different clinics, was found to be highly effective both in short-term and mid-term in oncology patients.
Keywords : Neuropathic pain; pregabalin; treatment